CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer

por Ogimoto, Tatsuya, Ozasa, Hiroaki, Yoshida, Hironori, Nomizo, Takashi, Funazo, Tomoko, Yoshida, Hiroshi, Hashimoto, Kentaro, Hosoya, Kazutaka, Yamazoe, Masatoshi, Ajimizu, Hitomi, Tsuji, Takahiro, Sakamori, Yuichi, Kuninaga, Kiyomitsu, Morita, Satoshi, Hirai, Toyohiro
Publicado 2023

Yes‐associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1‐rearranged lung cancer

por Yamazoe, Masatoshi, Ozasa, Hiroaki, Tsuji, Takahiro, Funazo, Tomoko, Yoshida, Hiroshi, Hashimoto, Kentaro, Hosoya, Kazutaka, Ogimoto, Tatsuya, Ajimizu, Hitomi, Yoshida, Hironori, Itotani, Ryo, Sakamori, Yuichi, Kuninaga, Kiyomitsu, Aoki, Wataru, Hirai, Toyohiro
Publicado 2022

Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer

por Ajimizu, Hitomi, Ozasa, Hiroaki, Sato, Susumu, Funazo, Tomoko, Sakamori, Yuichi, Nomizo, Takashi, Kuninaga, Kiyomitsu, Ogimoto, Tatsuya, Hosoya, Kazutaka, Yamazoe, Masatoshi, Tsuji, Takahiro, Yoshida, Hironori, Itotani, Ryo, Ueno, Kentaro, Kim, Young Hak, Muro, Shigeo, Hirai, Toyohiro
Publicado 2021

Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer

por Ajimizu, Hitomi, Ozasa, Hiroaki, Sato, Susumu, Funazo, Tomoko, Sakamori, Yuichi, Nomizo, Takashi, Kuninaga, Kiyomitsu, Ogimoto, Tatsuya, Hosoya, Kazutaka, Yamazoe, Masatoshi, Tsuji, Takahiro, Yoshida, Hironori, Itotani, Ryo, Ueno, Kentaro, Kim, Young Hak, Muro, Shigeo, Hirai, Toyohiro
Publicado 2023